Results 261 to 270 of about 863,721 (336)

Psoas abscess caused by non-typhoid Salmonella in a man with human immunodeficiency virus (HIV): A rare case report. [PDF]

IDCases
Habous M, Aldabal L, Lone R, Alatoom A, Nabi A, Monga R, Mathur B.   +6 more
europepmc   +1 more source

Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long‐Acting Intramuscular Injections

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting cabotegravir is approved for HIV treatment and prevention. To guide management of dosing deviations and interruptions, concentration‐time profiles for monthly and every 2 months regimens were simulated using a population pharmacokinetic (PPK) model.
Kelong Han, Ronald D. D'Amico, William R. Spreen, Susan L. Ford   +3 more
wiley   +1 more source

Vitamin D Receptor Gene FokI Polymorphism in Patient with Human Immunodeficiency Virus - Tuberculosis Coinfection and Associated Risk Factors. [PDF]

Infect Chemother
Gayatri AAAY, Ayu Dewi NN, Wiratnaya IGE, Merati KTP.   +3 more
europepmc   +1 more source

HAMPAO-SPECT of the brain and ocular microangiopathic syndrome in patients infected with the human immunodeficiency virus type 1 [PDF]

, 1993
Bogner, Johannes R., Einhäupl, Karl Max, Geier, Stephan A., Goebel, Frank-Detlef, Hammel, Gertrud, Sadri, Ifna, Schielke, Eva, Tatsch, Klaus   +7 more
core  

Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

Clinical Pharmacology in Drug Development, EarlyView.
Abstract AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442
Nanyang Li, Jing Zhang, Wenhong Zhang, Zhongyuan Xu, Xiangcao Yao, Anqi He, Shuyuan Liu, Xiaoyun Ge, Jinxi Liu, Yunfei Li, Cecil Chi‐Keung Chen, Huixia Zhang   +11 more
wiley   +1 more source

The Prevalence of Cardiovascular Disease Risk Factors on Diabetic Human Immunodeficiency Virus-Infected Individuals on Antiretroviral Treatment: A Systematic Review and Meta-Analysis Protocol. [PDF]

Health Sci Rep
Maswanganyi K, Sedibe A, Mzimela NC, Gamede M.   +3 more
europepmc   +1 more source

CORRECTION OF EQUINE SEVERE COMBINED IMMUNODEFICIENCY BY BONE MARROW TRANSPLANTATION

, 1986
Charles M. Bue, William C. Davis, Nancy S. Magnuson, Vilma D. Mottironi, Hans D. Ochs, Carol R. Wyatt, Lance E. Perryman   +6 more
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Trends Following Lumbar Spine Fusion in People Living With Human Immunodeficiency Virus in New York State. [PDF]

Cureus
Duah BA, Botros M, Benn L, Yoon K, Joo P, Ramirez G, Thirukumaran C, Mesfin A.   +7 more
europepmc   +1 more source